



Helping the healthcare industry digitally transform R&D

De-risking innovation and increasing efficiency

New stringent regulations, an even stronger focus on safety, requests for personalized medicine or requests that take into account human variability, rare diseases and an aging population:

Trends that are asking for more innovation in a shorter time-frame, with already unsustainable costs, while governments have healthcare spends under scrutiny.

Digitalization has been the answer for safety critical sectors such as aerospace and automotive to the challenge of innovating faster while reducing costs and risks, but healthcare is still lagging behind.

Now, new technologies are making it easier for everybody to digitally transform R&D, opening the road also to new incumbents that can have the power of disrupting the industry.

Are you ready?

500 days saved

25% costs ⁽¹⁾

Impact of digital technologies on new drugs development.

45% ⁽²⁾

Of the evidences used in approval process for medical devices will be simulation-related vs today's 10%.

The imperative for medical technology companies is to move quickly to adopt digital platforms. If they don't, it's only a matter of time before the digital disruptors move in. ⁽³⁾

1. McKinsey & Co - The pursuit of excellence in new-drug development

2. FDA - T. Morrison - State of digital evidence in medical devices

3. Accenture Life Sciences - Taking advantage of digital platforms for medical technology


How we accelerate digitalization in Pharma & MedTech

InSilicoTrials is the Modeling and Simulation cloud platform that accelerates R&D and regulatory approval for drugs and medical devices.



Validated Models

Made by top scientists and universities
Supported by scientific evidences and publications
Locked to ensure integrity



Unified Interface

Simplified UI
One interface for multiple models
Guided workflows
Ready to use reports



Cloud-Based

Embedded simulation engines
Unlimited and flexible
Multiple solvers embedded
Resilient and accessible
Cybersecure
Turnkey ready

3 pillars for a new paradigm

In Silico requires validated models and know-how

With our unique “crowdsience” approach, we give access to validated models based on strong scientific evidence, that are already compliant with regulatory requirements.

The platform grants models’ integrity.
The knowledge embeded in them can be used with confidence.

In Silico requires new skills and a new mindset

We provide simplified user interfaces and automated workflows, whose inputs are data. No need to learn new software or new concepts.

Our consultancy team helps our clients to design, plan and execute R&D path and In silico trials, to get reports in line with regulatory requirements.

In Silico requires dedicated resources and infrastructure

Our cloud-based, cybersecure platform allows scattered teams to exploit the power of the best solvers and optimized hardware without the need of buying, maintaining and learning how to use them.

Resources are flexible: use what you need, when you need it, and pay just that.

4 ways of working together

Open Platform

Buy tokens and use the models of your choice among those available on the platform.

On Demand & Custom

Ask for the models and simulations you need, to evaluate where modeling and simulation can support you.

Virtual Patients

Design and accelerate your clinical trials with with the cohorst of virtual patients on demand.

Support & Services

In silico trials planning, execution and reporting, in line with regulatory requirements.